Sign Up Today and Learn More About BigHat Biosciences Stock
Invest in or calculate the value of your shares in BigHat Biosciences or other pre-IPO companies through EquityZen's platform.
BigHat Biosciences Stock (BIBI)
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
About BigHat Biosciences Stock
Founded
2019
Headquarters
San Mateo, CA, US
Industries
Software, Data and Analytics, Science and Engineering
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
BigHat Biosciences Press Mentions
Stay in the know about the latest news on BigHat Biosciences
Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
prnewswire • Nov 04, 2024
Tech driven biology and chemistry: Solving science’s hardest problems at scale
TechCrunch • Aug 05, 2024
Liz Schwarzbach, Chief Business Officer at BigHat Biosciences
linkedin • Aug 05, 2024
BigHat Biosciences Enters Into Strategic Collaboration to Leverage Machine Learning in Antibody Discovery & Design
finance • Jun 25, 2024
AbbVie partners with BigHat to develop antibody therapies
pharmaceutical-technology • May 24, 2024
Investors in BigHat Biosciences
Discover investors in BigHat Biosciences stock and explore their portfolio companies
BigHat Biosciences Management
Leadership team at BigHat Biosciences
Co-Founder and CEO
Mark DePristo
Co-Founder and CSO
Peyton Greenside
Join now and verify your accreditation status to gain access to:
- BigHat Biosciences current valuation
- BigHat Biosciences stock price
- Available deals in BigHat Biosciences and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in BigHat Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like BigHat Biosciences through EquityZen funds. These investments are made available by existing BigHat Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell BigHat Biosciences stock?
Shareholders can sell their BigHat Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
